Renal Nerve Denervation After Pulmonary Vein Isolation for Persistent Atrial Fibrillation

Renal Artery Sympathetic Denervation by Catheter Ablation After Pulmonary Vein Isolation for Persistent Atrial Fibrillation

Atrial fibrillation (AF) is the most common arrhythmia and it is associated with significant morbidity and mortality. Electrical isolation of the pulmonary vein (PVI) by radiofrequency energy or cryoablation has been shown to be an effective treatment of AF by reducing morbidity, improving quality of life and functional capacity.

Renal artery sympathetic denervation (RND) by catheter ablation has been shown in a preliminary study to improve outcome of PVI in patients with paroxysmal and/or persistent AF with concomitant refractory or moderate hypertension. In patients with renal impairment, RND also conferred benefit in reducing AF recurrence after PVI. The initial indication for catheter-based RND is for blood pressure control in patients with resistant hypertension. However, a recent study failed to show significant difference in blood pressure reduction by RND. Therefore, the effect of RND on AF suppression may be independent of blood pressure control. Possible mechanisms of RND on AF may include risk factors modification and anti-arrhythmic effect.

Study Overview

• Status: Terminated
• Conditions: Atrial Fibrillation
• Intervention / Treatment: Procedure: Pulmonary vein isolation; Procedure: Renal Nerve Denervation

Detailed Description

This prospective randomized study aimed to evaluate the effect of RDN added to PVI for persistent AF. Study will be performed in accordance with Declaration of Helsinki.

Study Hypothesis: Catheter based RDN can prevent recurrence of AF in patient with persistent AF undergoing PVI by mechanism not related to hypertension control.

Primary outcome measure: Freedom from documented AF episodes post PVI as defined by longer than 30 seconds of AF recorded by implantable loop recorder 2 to 18 months after procedure with or without antiarrhythmic medication.

Sample Size:

This is an exploratory study, the sample size calculation will not be applied and arbitrary assign 20 subjects to each arm will be adopted.

Randomization Arms:

Patients are randomized in 1:1 fraction to one of the following arms:

1. PVI by cryo-balloon ablation without linear ablation;
2. PVI by cryo-balloon ablation without linear ablation plus bilateral RND using a multi-electrode renal denervation catheter.

• Study Type: Interventional
• Enrollment (Actual): 3
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Hong Kong
  • Hong Kong, Hong Kong
    • The Chinese University of Hong Kong

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients age is 18 years or greater;
2. Patients undergoing a first-time ablation procedure for AF;
3. Patients with persistent AF;
4. Persistent AF will be defined as a sustained episode lasting > 7 days and less than 3 years.
5. Patients with symptomatic AF that is refractory to at least one antiarrhythmic medication;
6. Symptomatic patients are those who have been aware of their AF at any time within the last 5 years prior to enrollment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms, or any combination of the above.
7. At least one episode of persistent AF must have been documented by ECG, Holter, loop recorder, telemetry, trans telephonic monitoring (TTM), or implantable device within last 2 years of enrollment in this investigation.

Exclusion Criteria:

1. Patients with paroxysmal AF;
2. Paroxysmal AF will be defined as a sustained episode lasting < 7 days.
3. Patients with long-standing persistent AF;
4. Long-standing persistent AF will be defined as a sustained episode lasting more than 3 years;
5. Patients for whom cardioversion or sinus rhythm will never be attempted/pursued;
6. Patients with AF felt to be secondary to an obvious reversible cause;
7. Patients with contraindications to systemic anticoagulation with heparin or warfarin or a direct thrombin inhibitor;
8. Patients with left atrial size ≥ 60 mm (2D echocardiography, parasternal long axis view);
9. Patients with more than 50% renal artery stenosis identified by duplex ultrasound or renal angiogram;
10. Patients in whom a renal stent has been in place for less than3 months;
11. Patients with prior renal artery stent placement, the artery segment beyond the stent margins must be able to accommodate treatments;
12. Patients with the treatment zone for denervation in the renal artery have areas of atheroma, severe fibromuscular dysplasia, calcification, and aneurysm that cannot be avoided;
13. Patients with renal dysfunction as demonstrated by an estimated glomerular filtration rate less than 45 mL/min per 1.73 m2 are excluded from both studies;
14. Pregnant women;
15. Participation in another interventional study;
16. Patient with contraindication to left ventricle catheterization by a retrograde aortic approach (eg mechanical aortic valve, severe aortic stenosis and aortic dissection).
17. Patient with systolic blood pressure <100mmHg.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Pulmonary vein isolation alone; PVI by cryo-balloon ablation without linear ablation	Procedure: Pulmonary vein isolation; PVI by cryo-balloon ablation without linear ablation; Other Names: PVI
Experimental: Renal nerve denervation; PVI by cryo-balloon ablation without linear ablation plus bilateral RND using a multi-electrode renal denervation catheter.	Procedure: Pulmonary vein isolation; PVI by cryo-balloon ablation without linear ablation; Other Names: PVI; Procedure: Renal Nerve Denervation; Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.; Other Names: Renal artery sympathetic nerve denervation; RND

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Freedom from documented AF episodes post PVI by implantable loop recorder by implantable loop recorder.	Freedom from documented AF episodes post PVI as defined by longer than 30 seconds of AF recorded by implantable loop recorder 2 to 18 months after procedure with or without antiarrhythmic medication.	2 to 18 months after procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of repeat procedures	Number of repeat procedures	18 months
Freedom from documented atrial arrhythmia episodes post PVI by implantable loop recorder.	Freedom from documented atrial arrhythmia episodes post PVI as defined by longer than 30 seconds of atrial arrhythmia recorded by implantable loop recorder 2 to 18 months after procedure with or without antiarrhythmic medication.	2 to 18 months after procedure
Freedom from symptomatic AF episodes post PVI by implantable loop recorder.	Freedom from symptomatic AF episodes post PVI as defined by longer than 30 seconds of AF recorded by implantable loop recorder 2 to 18 months after procedure with or without antiarrhythmic medication.	2 to 18 months after procedure
Freedom from symptomatic atrial arrhythmia episodes post PVI by implantable loop recorder.	Freedom from symptomatic atrial arrhythmia episodes post PVI as defined by longer than 30 seconds of atrial arrhythmia recorded by implantable loop recorder 2 to 18 months after procedure with or without antiarrhythmic medication.	2 to 18 months after procedure
Freedom from documented AF episodes post PVI by hand-held smartphone device.	Freedom from documented AF episodes post PVI as defined by 30 seconds of AF recorded by hand-held smartphone device (i.e. Cardiio Rhythm iPhone AF-detection system or AliveCor single-lead ECG device) 2 to 18 months after procedure with or without antiarrhythmic medication.	2 to 18 months after procedure
The mean blood pressure as measured by 24-hour ambulatory blood pressure monitoring.	The mean blood pressure as measured by 24-hour ambulatory blood pressure before and after ablation up to 36 months.	18 months
Incidence of peri-procedural complications.	Incidence of peri-procedural complications, including stroke, PV stenosis, cardiac perforation, phrenic nerve palsy, esophageal injury and death.	18 months
Procedure duration	Procedure duration	duing procedure
Fluoroscopy time during procedure	Fluoroscopy time during procedure	dueing procedure

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong
• Investigators: Principal Investigator: Bryan Ping Yen Yan, Chinese University of Hong Kong

Study record dates

Study Major Dates

• Study Start (Actual): September 17, 2018
• Primary Completion (Actual): August 31, 2020
• Study Completion (Actual): August 31, 2020

Study Registration Dates

• First Submitted: August 9, 2017
• First Submitted That Met QC Criteria: August 9, 2017
• First Posted (Actual): August 11, 2017

Study Record Updates

• Last Update Posted (Actual): October 26, 2021
• Last Update Submitted That Met QC Criteria: October 18, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: Ablation; Renal Denervation; Cryoballoon
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Atrial Fibrillation
• Other Study ID Numbers: CUHK-CARD-2017-RND

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No